Potential value of circulatory microRNA122 gene expression as a prognostic and metastatic prediction marker for breast cancer

Saleh, Amany A.; Soliman, Shimaa E.; Habib, Mona Salah El‐din; Gohar, Suzy; Abo-Zeid, Ghada S.

doi:10.1007/s11033-019-04727-5

Cited by 25 publications

(12 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miR‐122‐5p has been thoroughly studied in human breast cancers, and its high expression level is associated with poor survival outcomes (Saleh, Soliman, Habib, Gohar, & Abo‐Zeid, ). In addition, miR‐122‐5p affects tumor progression by targeting a panel of human genes such as UCA‐1, SDC1 , and c‐MYC and so forth (Ergün et al, ; Pourteimoor, Paryan, & Mohammadi‐Yeganeh, ; Uen et al, ; Wang, Wang, & Yang, ; Yan, Zhang, Fan, Li, & Zhou, ; Zhou et al, ).…”

Section: Discussionmentioning

confidence: 99%

“…(Figure 4a,b). Then the forced expression of CHMP3 by transfecting the CHMP3 gene clone plasmids caused significantly overexpressed CHMP3 mRNA and protein (Figure 4c,d) miR-122-5p has been thoroughly studied in human breast cancers, and its high expression level is associated with poor survival outcomes (Saleh, Soliman, Habib, Gohar, & Abo-Zeid, 2019). In addition, miR-122-5p affects tumor progression by targeting a panel of human genes such as UCA-1, SDC1, and c-MYC and so forth (Ergün et al, 2015;Pourteimoor, Paryan, & Mohammadi-Yeganeh, 2018;Uen et al, 2018;Wang, Wang, & Yang, 2012;Yan, Zhang, Fan, Li, & Zhou, 2014;Zhou et al, 2018).…”

Section: Cell Proliferation and Apoptosis Analysismentioning

confidence: 99%

See 1 more Smart Citation

miR‐122‐5p promotes aggression and epithelial‐mesenchymal transition in triple‐negative breast cancer by suppressing charged multivesicular body protein 3 through mitogen‐activated protein kinase signaling

Wang

2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is highly metastatic and frequently has a poor prognosis. The lack of comprehension of TNBC and gene therapy targets has led to limitedly effective treatment for TNBC. This study was conducted to better understand the molecular mechanism behind TNBC progression, and to find out promising gene therapy targets for TNBC. Herein the influence of miR-122-5p's binding charged multivesicular body protein 3 (CHMP3) 3′-untranslated region (3′-UTR) on in TNBC cells was investigated. in vitro experiments quantitative real-time polymerase chain reaction, immunoblot analysis, dual-luciferase reporter gene assay, cell counting assay, transwell invasion assay, and flow cytometry-determined cell apoptosis assay were employed. We also used TargetScan Human 7.2 database to find out the target relationship between miR-122-5p and CHMP3 3′-UTR. TImer algorithm was used to provide an overview of the expression of CHMP3 gene across human pan-cancer, to predict the survival outcome of breast cancer patients, and to predict the correlation between CHMP3 gene expression and epithelial-mesenchymal transition (EMT) and mitogen-activated protein kinase (MAPK)-related gene expression. CHMP3 gene was significantly downregulated across a wide range of human cancers including breast cancer (BRCA). A higher level of CHMP3 gene predicted a better 3-and 5-year survival outcome of patients with BRCA. In our experiments, miR-122-5p was significantly upregulated and CHMP3 gene was significantly downregulated in TNBC cells compared with normal cell line. miR-122-5p mimics enhanced TNBC cell viability, proliferation, and invasion whereas the upregulation of CHMP3 gene led to an opposite outcome.Forced expression of miR-122-5p suppressed cell apoptosis, compelled EMT and MAPK signaling whereas forced expression of CHMP3 did the opposite. We then conclude that miR-122-5p promotes aggression and EMT in TNBC by suppressing CHMP3 through MAPK signaling. K E Y W O R D S CHMP3, EMT, MAPK, miR-122-5p, triple-negative breast cancer *Zheng Wang and Xiangyu Wang contributed equally to this work.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Cell Proliferation and Apoptosis Analysismentioning

confidence: 99%

miR‐122‐5p promotes aggression and epithelial‐mesenchymal transition in triple‐negative breast cancer by suppressing charged multivesicular body protein 3 through mitogen‐activated protein kinase signaling

Wang

2019

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…Expression levels of miR-21, miR-23b, miR-200c, and miR-200b were upregulated in metastatic breast cancer when compared to early breast cancer patients, therefore supporting the notion that ccfmiRNAs presents a tool with the crucial diagnostic and prognostic implication in breast cancer (Papadaki et al, 2019). Furthermore, a study discovered that increased miR-122 expression was significantly associated with a reduction in the overall survival as well as progression-free survival in breast cancer patients (Saleh et al, 2019). Elevation in the levels of serum miR-29, miR-122, miR-155, and miR-192 was observed in cholangiocarcinoma.…”

Section: Ccfmirnas In Cancermentioning

confidence: 59%

Circulating Cell-Free Nucleic Acids as Epigenetic Biomarkers in Precision Medicine

et al. 2020

View full text Add to dashboard Cite

The circulating cell-free nucleic acids (ccfNAs) are a mixture of single-or doublestranded nucleic acids, released into the blood plasma/serum by different tissues via apoptosis, necrosis, and secretions. Under healthy conditions, ccfNAs originate from the hematopoietic system, whereas under various clinical scenarios, the concomitant tissues release ccfNAs into the bloodstream. These ccfNAs include DNA, RNA, microRNA (miRNA), long non-coding RNA (lncRNA), fetal DNA/RNA, and mitochondrial DNA/RNA, and act as potential biomarkers in various clinical conditions. These are associated with different epigenetic modifications, which show disease-related variations and so finding their role as epigenetic biomarkers in clinical settings. This field has recently emerged as the latest advance in precision medicine because of its clinical relevance in diagnostic, prognostic, and predictive values. DNA methylation detected in ccfDNA has been widely used in personalized clinical diagnosis; furthermore, there is also the emerging role of ccfRNAs like miRNA and lncRNA as epigenetic biomarkers. This review focuses on the novel approaches for exploring ccfNAs as epigenetic biomarkers in personalized clinical diagnosis and prognosis, their potential as therapeutic targets and disease progression monitors, and reveals the tremendous potential that epigenetic biomarkers present to improve precision medicine. We explore the latest techniques for both quantitative and qualitative detection of epigenetic modifications in ccfNAs. The data on epigenetic modifications on ccfNAs are complex and often milieu-specific posing challenges for its understanding. Artificial intelligence and deep networks are the novel approaches for decoding complex data and providing insight into the decision-making in precision medicine.

show abstract

“…It was elucidated that oncogenic MiRNAs were considerably up regulated in cancer scenarios, whilst tumor-suppressive MiRNAs were repeatedly down regulated. The effectiveness of using miRNAs as diagnostic or prognostic biomarkers began to gain fundamental consideration in cancer research [ 21 , 22 ].…”

Section: Discussionmentioning

confidence: 99%

Down regulation of miR-30a-5p and miR-182–5p in gastric cancer: Clinical impact and survival analysis

Soliman

Elabd

El-Kousy

et al. 2021

Biochemistry and Biophysics Reports

Self Cite

View full text Add to dashboard Cite

Background and aim Gastric Cancer (GC) is a leading cause of morbidity and mortality worldwide, particularly in developing nations, only a few suitable gastric cancer serum biomarkers with acceptable sensitivity and specificity exist. This work aims to highlight and uncover miR-30a-5p and miR-182–5p′s diagnostic roles regarding gastric cancer and their roles in predicting prognosis. Methods 148 patients participated in this study. Groups I, II, and III had 47 patients with GC, 54 patients with benign gastric lesions, and 47 apparently healthy subjects of coincided age and gender as controls , respectively. All participants were clinically evaluated and subjected to CBC, serum CEA, and CA19-9 by ELISA, and real-time PCR tests of miR-30a-5p and miR-182–5p. Results MiR30a-5p and miR-182–5p were down regulated in gastric cancer patients in Group I more than Groups II and III (P < 0.001). ROC curve analysis revealed that miR30a-5p had better AUC, sensitivity, and specificity (0.961%, 93.62%, and 90.74%respectively). When miR-182–5p was gathered with CEA and CA19-9, specificity raised to 98.15% and PPV to 97.6%. Lower miR-30a-5p levels are linked with the presence of distant metastases, advanced TNM stage, and degree of pathological differentiation of tumors in GC patients (p = 0.034, 0.019, 0.049) respectively. According to the multivariate analysis, miR30a-5p expression level could be an independent predictor of GC. Conclusion Our results exhibited that miRNAs, miR-30a-5p and miR182–5p, gene expression have a diagnostic power and can identify patients with GC. MiR-30a-5p displayed the highest diagnostic specificity and sensitivity. Besides other known tumor markers, they could offer simple noninvasive biomarkers that predict gastric cancer.

show abstract

Potential value of circulatory microRNA122 gene expression as a prognostic and metastatic prediction marker for breast cancer

Cited by 25 publications

References 29 publications

miR‐122‐5p promotes aggression and epithelial‐mesenchymal transition in triple‐negative breast cancer by suppressing charged multivesicular body protein 3 through mitogen‐activated protein kinase signaling

miR‐122‐5p promotes aggression and epithelial‐mesenchymal transition in triple‐negative breast cancer by suppressing charged multivesicular body protein 3 through mitogen‐activated protein kinase signaling

Circulating Cell-Free Nucleic Acids as Epigenetic Biomarkers in Precision Medicine

Down regulation of miR-30a-5p and miR-182–5p in gastric cancer: Clinical impact and survival analysis

Contact Info

Product

Resources

About